Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Pharma, Inc.

74.60
-1.4850-1.95%
Volume:90.42K
Turnover:6.78M
Market Cap:14.61B
PE:-20.90
High:75.50
Open:75.27
Low:74.46
Close:76.08
52wk High:93.42
52wk Low:48.78
Shares:195.81M
Float Shares:167.00M
Volume Ratio:0.57
T/O Rate:0.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5686
EPS(LYR):-3.7850
ROE:-1789.67%
ROA:-26.00%
PB:-5.81
PE(LYR):-19.71

Loading ...

BridgeBio Pharma Q2 Loss Narrows, Revenue Rises

MT Newswires Live
·
Aug 11

Earnings Flash (BBIO) BridgeBio Pharma Posts Q2 Loss $0.78, vs. FactSet Est of $0.58 Loss

MT Newswires Live
·
Aug 11

BridgeBio Pharma Q2 EPS $(0.78) Misses $(0.59) Estimate, Sales $243.676M Beat $218.743M Estimate

Benzinga Earnings
·
Aug 11

BridgeBio Pharma Q2 Net Income USD -155.891 Million

Reuters
·
Aug 11

BridgeBio Pharma Q2 EPS USD -0.78

THOMSON REUTERS
·
Aug 11

U.S. Earnings Preview: After Market Close Aug. 10

Dow Jones
·
Aug 11

BridgeBio Pharma, Inc. Expected to Post a Loss of 58 Cents a Share - Earnings Preview

Reuters
·
Aug 08

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 07

BridgeBio Pharma Chief Accounting Officer Maricel Apuli Sells 2,000 Shares for $160,120

Reuters
·
Aug 04

BridgeBio Pharma to Report Q2 Financial Results, Provide Business Update on Conference Call

Reuters
·
Aug 03

BridgeBio (BBIO) Stock Still Looks Pricey After FDA Filing Acceptance

Simply Wall St.
·
Jul 29

BridgeBio Oncology Therapeutics Inc Expected to Post a Loss of 57 Cents a Share - Earnings Preview

Reuters
·
Jul 28

BridgeBio files to sell 24.63M shares of common stock for holders

TIPRANKS
·
Jul 25

Bridgebio Pharma Inc: Files for Offering of up to 24.6 Mln Common Shares by Selling Stockholders - SEC Filing

THOMSON REUTERS
·
Jul 25

Is FDA’s Encaleret NDA Acceptance Redefining the Investment Case For BridgeBio Pharma (BBIO)?

Simply Wall St.
·
Jul 24

BridgeBio announces FDA acceptance of encaleret NDA

TIPRANKS
·
Jul 22

Bridgebio Says FDA Accepts Encaleret NDA for ADH1, Sets May 8, 2027 PDUFA Date

Reuters
·
Jul 22

Bridgebio Pharma - to Initiate Reclaim-hp Phase 3 Study of Encaleret in Chronic Hypoparathyroidism

THOMSON REUTERS
·
Jul 22

Bridgebio Pharma - FDA not Planning Advisory Committee Meeting for Encaleret Nda

THOMSON REUTERS
·
Jul 22

Bridgebio Announces FDA Acceptance of Nda for Encaleret for Adh1

THOMSON REUTERS
·
Jul 22